Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T06011
(Former ID: TTDC00203)
|
|||||
| Target Name |
Transforming growth factor beta (TGFB)
|
|||||
| Synonyms |
TGF-beta
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 9 Target-related Diseases | + | ||||
| 1 | Brain cancer [ICD-11: 2A00] | |||||
| 2 | Chronic kidney disease [ICD-11: GB61] | |||||
| 3 | Myeloproliferative neoplasm [ICD-11: 2A20] | |||||
| 4 | Non-small-cell lung cancer [ICD-11: 2C25] | |||||
| 5 | Pancreatic cancer [ICD-11: 2C10] | |||||
| 6 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| 7 | Ureteral cancer [ICD-11: 2C92] | |||||
| 8 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
| 9 | Anemia [ICD-11: 3A00-3A9Z] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | M7824 | Drug Info | Phase 2 | Solid tumour/cancer | [1], [5] | |
| 2 | NIS793 | Drug Info | Phase 2 | Pancreatic ductal carcinoma | [6] | |
| 3 | TEW-7197 | Drug Info | Phase 2 | Myeloproliferative neoplasm | [7] | |
| 4 | ACE-011 | Drug Info | Phase 1 | Anemia | [12] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 3 Inhibitor drugs | + | ||||
| 1 | M7824 | Drug Info | [1] | |||
| 2 | NIS793 | Drug Info | [1] | |||
| 3 | ACE-011 | Drug Info | [12] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | TEW-7197 | Drug Info | [1] | |||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 2 | ClinicalTrials.gov (NCT01113801) A Study in Patients With Diabetic Kidney Disease. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT01472731) Safety and Imaging Study of GC1008 in Glioma. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 6 | ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT04103645) Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients. U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT03834662) A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies. U.S. National Institutes of Health. | |||||
| REF 9 | ClinicalTrials.gov (NCT03954704) Study of GS-1423 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 10 | ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 11 | Clinical pipeline report, company report or official report of Roche | |||||
| REF 12 | Clinical pipeline report, company report or official report of Acceleron Pharma (2011). | |||||
| REF 13 | Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.